UroGen Pharma Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $16.06
- Today's High:
- $16.88
- Open Price:
- $16.76
- 52W Low:
- $7.075
- 52W High:
- $24.13
- Prev. Close:
- $16.68
- Volume:
- 171083
Company Statistics
- Market Cap.:
- $513.86 million
- Book Value:
- -5.891
- Revenue TTM:
- $72.52 million
- Operating Margin TTM:
- -104.52%
- Gross Profit TTM:
- $56.70 million
- Profit Margin:
- -150.37%
- Return on Assets TTM:
- -39.23%
- Return on Equity TTM:
- -1481.26%
Company Profile
UroGen Pharma Ltd had its IPO on 2017-05-04 under the ticker symbol URGN.
The company operates in the Healthcare sector and Biotechnology industry. UroGen Pharma Ltd has a staff strength of 193 employees.
Stock update
Shares of UroGen Pharma Ltd opened at $16.76 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $16.06 - $16.88, and closed at $16.15.
This is a -3.18% slip from the previous day's closing price.
A total volume of 171,083 shares were traded at the close of the day’s session.
In the last one week, shares of UroGen Pharma Ltd have slipped by -10.97%.
UroGen Pharma Ltd's Key Ratios
UroGen Pharma Ltd has a market cap of $513.86 million, indicating a price to book ratio of 16.0495 and a price to sales ratio of 2.9251.
In the last 12-months UroGen Pharma Ltd’s revenue was $72.52 million with a gross profit of $56.70 million and an EBITDA of $-74895000. The EBITDA ratio measures UroGen Pharma Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, UroGen Pharma Ltd’s operating margin was -104.52% while its return on assets stood at -39.23% with a return of equity of -1481.26%.
In Q2, UroGen Pharma Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 27.3%.
UroGen Pharma Ltd’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-4.35 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into UroGen Pharma Ltd’s profitability.
UroGen Pharma Ltd stock is trading at a EV to sales ratio of 2.5809 and a EV to EBITDA ratio of -1.9404. Its price to sales ratio in the trailing 12-months stood at 2.9251.
UroGen Pharma Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $95.36 million
- Total Liabilities
- $26.77 million
- Operating Cash Flow
- $3.72 million
- Capital Expenditure
- $15000
- Dividend Payout Ratio
- 0%
UroGen Pharma Ltd ended 2024 with $95.36 million in total assets and $0 in total liabilities. Its intangible assets were valued at $95.36 million while shareholder equity stood at $-138434000.00.
UroGen Pharma Ltd ended 2024 with $0 in deferred long-term liabilities, $26.77 million in other current liabilities, 64000.00 in common stock, $-631453000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $20.13 million and cash and short-term investments were $47.30 million. The company’s total short-term debt was $0 while long-term debt stood at $98.30 million.
UroGen Pharma Ltd’s total current assets stands at $81.33 million while long-term investments were $7.97 million and short-term investments were $27.17 million. Its net receivables were $15.51 million compared to accounts payable of $4.66 million and inventory worth $4.99 million.
In 2024, UroGen Pharma Ltd's operating cash flow was $3.72 million while its capital expenditure stood at $15000.
Comparatively, UroGen Pharma Ltd paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $16.15
- 52-Week High
- $24.13
- 52-Week Low
- $7.075
- Analyst Target Price
- $23
UroGen Pharma Ltd stock is currently trading at $16.15 per share. It touched a 52-week high of $24.13 and a 52-week low of $24.13. Analysts tracking the stock have a 12-month average target price of $23.
Its 50-day moving average was $16.19 and 200-day moving average was $11.38 The short ratio stood at 1.31 indicating a short percent outstanding of 0%.
Around 979.4% of the company’s stock are held by insiders while 6667.9% are held by institutions.
Frequently Asked Questions About UroGen Pharma Ltd
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.